Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression
Research output: Contribution to journal › Research article › Contributed › peer-review
Contributors
Abstract
Purpose: To compare functional effects of combined irradiation and EGFR inhibition in different HNSCC tumour models in vivo with the results of molecular evaluations, aiming to set a basis for the development of potential biomarkers for local tumour control. Material and methods: In five HNSCC tumour models, all wild-type for EGFR and KRAS, the effect of radiotherapy alone (30 fractions/6 weeks) and with simultaneous cetuximab or erlotinib treatment on local tumour control were evaluated and compared with molecular data on western blot, immunohistochemistry and fluorescence-in situ-hybridisation (FISH). Results: Erlotinib and cetuximab alone significantly prolonged tumour growth time in 4/5 tumour models. Combined irradiation and cetuximab treatment significantly improved local tumour control in 3/5 tumour models, whereas erlotinib did not alter local tumour control in any of the tumour models. The amount of the cetuximab-effect on local tumour control significantly correlated with the EGFR/CEP-7 ratios obtained by FISH. Conclusion: Both drugs prolonged growth time in most tumour models, but only application of cetuximab during irradiation significantly improved local tumour control in 3/5 tumour models. The significant correlation of this curative effect with the genetic EGFR expression measured by FISH will be further validated in preclinical and clinical studies.
Details
Original language | English |
---|---|
Pages (from-to) | 323-330 |
Number of pages | 8 |
Journal | Radiotherapy and Oncology |
Volume | 99 |
Issue number | 3 |
Publication status | Published - Jun 2011 |
Peer-reviewed | Yes |
External IDs
Scopus | 79960352442 |
---|---|
PubMed | 21665304 |
researchoutputwizard | legacy.publication#42770 |
researchoutputwizard | legacy.publication#42984 |
ORCID | /0000-0003-1526-997X/work/142247220 |
ORCID | /0000-0003-1776-9556/work/171065645 |
Keywords
Sustainable Development Goals
ASJC Scopus subject areas
Keywords
- Cetuximab, Combined treatment, EGFR inhibition, Erlotinib, Head and neck cancer, Prediction, Radiotherapy